Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
スポンサーリンク
概要
- 論文の詳細を見る
- 2009-11-20
著者
-
YAMAMURA AYUKO
Lilly Research Laboratories Japan, Eli Lilly Japan KK, Sannomiya Plaza Bldg.
-
WOLKA ANNE
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center
-
Wolka Anne
Lilly Research Laboratories Eli Lilly And Company Lilly Corporate Center
-
Yamamura Ayuko
Lilly Research Laboratories Japan Eli Lilly Japan K.k.
-
Iwamoto Kazuya
Lilly Research Laboratories Japan Eli Lilly Japan K.k.
-
NASU RISA
Lilly Research Laboratories Japan, Eli Lilly Japan K.K.
-
KOTHARE PRAJAKTI
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center
-
MACE KENNETH
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center
-
LINNEBJERG HELLE
Lilly Research Centre, Eli Lilly and Company Limited
-
Nasu Risa
Lilly Research Laboratories Japan Eli Lilly Japan K.k.
-
Kothare Prajakti
Lilly Research Laboratories Eli Lilly And Company Lilly Corporate Center
-
Mace Kenneth
Lilly Research Laboratories Eli Lilly And Company Lilly Corporate Center
-
Linnebjerg Helle
Lilly Research Centre Eli Lilly And Company Limited
関連論文
- Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes